Kazia Therapeutics Ltd (NASDAQ: KZIA)

Kazia Therapeutics Limited is an emerging oncology-focused biotechnology company engaged in pharmaceutical drug development. The company has a portfolio of development candidates diversified across several distinct technologies with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. Its lead program is Paxalisib an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway designed to treat brain cancer. The company is also developing EVT801 a small-molecule selective inhibitor of VEGFR3 targeting lymphangiogenesis and tumor immune micro-environment modulation. Kazia Therapeutics Limited operates primarily in the biotechnology and pharmaceutical industry with a focus on oncology therapeutics.

The company generates revenue through the potential commercialization of its drug candidates Paxalisib and EVT801 upon successful clinical development regulatory approval and market launch. Revenue is expected to come from product sales licensing agreements milestone payments and royalties. Currently the company does not have commercial products on the market and relies on funding from capital raising activities including at-the-market facilities private placements and equity lines of credit to support its research and development operations. The general customer base for future products would include hospitals oncology treatment centers and patients suffering from various cancer indications.

The company operates through the following segments: Paxalisib and EVT801.

• Paxalisib is an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. It is being developed for the treatment of brain cancers including glioblastoma glioma diffuse intrinsic pontine glioma and brain metastases. Paxalisib is orally administered in a 15mg capsule formulation and has received multiple regulatory designations including Orphan Drug Designation Fast Track Designation and Rare Pediatric Disease Designation from the U. S. Food and Drug Administration. The development candidate is the subject of IND 112608 with the FDA and is supported by a robust intellectual property portfolio with patent protection expected to extend through 2036 in key territories.

• EVT801 is a small-molecule selective inhibitor of VEGFR3. It is being developed to target lymphangiogenesis the formation of new lymphatic vessels and to modulate the tumor immune micro-environment. EVT801 was licensed from Evotec SE in April 2021 and is protected by granted or pending composition-of-matter patents in all key territories with exclusivity generally through the early 2030s. The drug is being evaluated in a phase I first-in-human clinical trial for advanced solid tumors with a recommended phase 2 dose of 400mg twice daily when given as a monotherapy. Clinical activity has been observed in High Grade Serous ovarian cancer patients with biomarker evidence supporting VEGFR3 expression and immune micro-environment modulation.

Kazia Therapeutics Limited operates in a highly competitive oncology biotechnology industry where it faces competition from large pharmaceutical companies and other biotechnology firms developing PI3K inhibitors angiogenesis inhibitors and lymphangiogenesis inhibitors. The company's competitive advantages include Paxalisib's unique ability to cross the blood-brain barrier a critical prerequisite for treating brain cancer which distinguishes it from other PI3K inhibitors in clinical development. Additionally EVT801's selective targeting of lymphangiogenesis offers a distinct mechanism of action compared to traditional angiogenesis inhibitors potentially overcoming hypoxia-induced resistance and toxicity issues. The company benefits from a strong intellectual property portfolio multiple FDA regulatory designations and collaborations with leading research institutions.

The company serves patients hospitals and oncology treatment centers. Specific customer names are not disclosed in the filing but the clinical trials are conducted in collaboration with prominent medical institutions including Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Weill Cornell Medicine St Jude Children's Research Hospital University of Sydney Pacific Pediatric Neuro-Oncology Consortium and Australian and New Zealand Children's Haematology/Oncology Group. These partnerships indicate a customer base comprising major cancer research and treatment organizations focused on advancing novel therapies for brain cancer and other solid tumors.